Analytical Data
-
Gene name
GlyT1
- Application
-
Alternative Names
Sodium- and chloride-dependent glycine transporter 1; Solute carrier family 6 member 9; SLC6A9; Homo sapiens; Human; GlyT-1
-
Species
Human
-
Source
HEK293
-
Tag
His;GFP
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P48067
-
Expression Region
M1-I706, L153A, S297A, I368A, C633A, del 1–90, del 240–256, del 685–706
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC12A1, a member of the solute carrier family, encodes a key transporter responsible for the reabsorption of sodium and chloride in the kidneys, playing a crucial role in maintaining electrolyte balance and blood pressure homeostasis. Mutations in the SLC12A1 gene have been linked to genetic forms of hypertension, such as Gitelman syndrome, characterized by hypokalemic metabolic alkalosis, hypomagnesemia, and renal wasting of electrolytes. Research on recombinant SLC12A1 protein is pivotal for understanding its functional mechanisms and the pathophysiology of related disorders. The expression of SLC12A1 in heterologous systems allows for detailed biochemical and pharmacological studies, offering insights into the transport processes and interactions with pharmacological agents. Furthermore, such studies may facilitate the development of targeted therapies for diseases associated with SLC12A1 dysfunction. As the normotensive and hypertensive states are influenced by the function of renal transporters like SLC12A1, understanding its structure-function relationship through the analysis of recombinant proteins is essential. Research in this area additionally contributes to the broader field of membrane transport biology, potentially revealing novel therapeutic targets for managing hypertension and electrolyte imbalances.
